Hypoxia
Hypoxia is a condition in which the body — or a specific region of the body — is deprived of adequate oxygen supply relative to its needs. The word hypoxia comes from the Greek hypo (meaning under or below) and oxia (meaning oxygen) — literally meaning below-normal oxygen. Hypoxia is one of the most fundamental and consequential biological conditions in medicine — playing critical roles in cancer progression, cardiovascular disease, Sickle Cell Disease, neurodegeneration, high-altitude physiology and a wide range of other clinical conditions. Understanding how cells and tissues sense, respond to and are damaged by hypoxia is one of the most important areas of modern biomedical research — and has been the focus of the Nobel Prize in Physiology or Medicine (2019), awarded to William Kaelin Jr., Sir Peter Ratcliffe and Gregg Semenza for their discoveries of how cells sense and adapt to oxygen availability.
Overview
Oxygen is the fundamental fuel of aerobic life — required by virtually every cell in the human body for the production of ATP (adenosine triphosphate) — the primary energy currency of cellular metabolism. When oxygen supply falls below a critical threshold, cells cannot produce adequate energy for their normal functions — triggering a cascade of molecular responses that can either help cells adapt and survive under low-oxygen conditions, or lead to cell damage and death.
Hypoxia exists on a spectrum — from mild, transient oxygen deficiency (such as that experienced at high altitude) to severe, sustained hypoxia (such as that occurring in the core of a solid tumour or during a heart attack) — with very different biological consequences depending on its severity, duration and the type of tissue affected.
Types of Hypoxia
Hypoxia is classified in several ways depending on its cause and context:
By Cause
Hypoxic Hypoxia
Hypoxic hypoxia (also called altitude hypoxia) occurs when the oxygen content of the air being breathed is too low — as occurs at high altitude where atmospheric pressure is reduced and oxygen partial pressure is lower. It is the type of hypoxia experienced by mountaineers, pilots and people living at high altitude.
Anaemic Hypoxia
Anaemic hypoxia occurs when the blood's capacity to carry oxygen is reduced — due to a deficiency of haemoglobin or red blood cells. It is characteristic of conditions including anaemia, Sickle Cell Disease and carbon monoxide poisoning — where haemoglobin's ability to carry oxygen is impaired.
Circulatory Hypoxia
Circulatory hypoxia (also called ischaemic hypoxia) occurs when blood flow to a tissue is insufficient to meet its oxygen needs — as occurs during a heart attack (myocardial infarction), stroke or pulmonary hypertension.
Histotoxic Hypoxia
Histotoxic hypoxia occurs when cells are unable to use the oxygen delivered to them — most commonly due to poisoning by substances such as cyanide that block cellular oxygen utilisation.
By Context
Tumour Hypoxia
Tumour hypoxia is one of the most clinically significant forms of hypoxia — occurring within solid tumours as they outgrow their blood supply. As a tumour grows, its rapidly dividing cells consume oxygen faster than it can be delivered by the existing blood vessels — creating regions of severe oxygen deficiency within the tumour core. Tumour hypoxia has profound consequences for cancer biology and treatment — making it one of the most important research areas in oncology.
Physiological Hypoxia
Physiological hypoxia refers to the normal, low-oxygen environments that exist in certain tissues of the body — including the bone marrow, the intestinal lining and certain embryonic tissues — where lower oxygen levels are part of the normal biological environment.
Chemical Hypoxia
Chemical hypoxia is induced experimentally using chemicals such as cobalt chloride (CoCl₂) — which mimic the cellular effects of hypoxia by stabilising the HIF-1α protein (see below) without actually reducing oxygen levels. Chemical hypoxia is widely used in laboratory research — including in studies of breast cancer conducted by researchers including Dr. Nishant Kumar Rana at Banaras Hindu University — to model the effects of tumour hypoxia on cancer cell behaviour.
Cellular Response to Hypoxia
When a cell experiences hypoxia, it activates a complex and highly conserved molecular response — primarily orchestrated by a family of proteins called Hypoxia-Inducible Factors (HIFs):
Hypoxia-Inducible Factor (HIF)
The Hypoxia-Inducible Factor (HIF) system is the master regulator of the cellular response to low oxygen — discovered by William Kaelin Jr., Sir Peter Ratcliffe and Gregg Semenza (2019 Nobel Prize in Physiology or Medicine).
HIF is a transcription factor — a protein that controls the expression of genes — consisting of two subunits:
- HIF-1α (or HIF-2α) — The oxygen-sensitive subunit — rapidly degraded under normal oxygen conditions but stabilised under hypoxia
- HIF-1β — The constitutively expressed subunit — always present in the cell
Under normal oxygen conditions, HIF-1α is continuously produced but also continuously destroyed — through a process involving the VHL (von Hippel-Lindau) tumour suppressor protein, which targets HIF-1α for degradation by the cellular protein disposal machinery (the proteasome).
Under hypoxic conditions, this degradation is inhibited — HIF-1α accumulates in the cell and pairs with HIF-1β to form an active transcription factor complex. This complex then travels to the nucleus and activates hundreds of target genes — initiating a comprehensive cellular adaptation programme.
Genes Activated by HIF
HIF activation triggers the expression of a broad programme of genes that help cells adapt to low oxygen:
- VEGF (Vascular Endothelial Growth Factor) — Stimulates the formation of new blood vessels (Angiogenesis) — bringing more oxygen to the hypoxic tissue
- Glycolytic enzymes — Shifting cellular energy production from oxygen-dependent oxidative phosphorylation to oxygen-independent glycolysis (the Warburg Effect)
- Erythropoietin (EPO) — Stimulating the production of red blood cells to increase oxygen-carrying capacity
- Glucose transporters (GLUT1, GLUT3) — Increasing glucose uptake for glycolytic energy production
- Carbonic anhydrase IX (CAIX) — Regulating cellular pH under hypoxic conditions
- Anti-apoptotic genes — Suppressing programmed cell death to help cells survive hypoxia
Hypoxia in Cancer
Hypoxia is one of the most important drivers of cancer progression — and understanding how tumours exploit hypoxia is a major focus of modern cancer research:
How Tumour Hypoxia Develops
As a solid tumour grows beyond approximately 1–2 mm in diameter, its rapidly proliferating cells begin to outpace the oxygen delivery capacity of the surrounding blood vessels. Regions of the tumour — particularly the core — become severely hypoxic. In response, tumour cells activate HIF — triggering VEGF-driven angiogenesis to recruit new blood vessels. However, tumour blood vessels are abnormal — leaky, tortuous and poorly organised — meaning that even with angiogenesis, tumour hypoxia often persists.
How Hypoxia Drives Cancer Aggressiveness
Tumour hypoxia has profound effects on cancer cell behaviour — making tumours more aggressive, more treatment-resistant and more likely to metastasise:
- Promotes metastasis — Hypoxia activates genes that enable cancer cells to invade surrounding tissues and enter the bloodstream
- Promotes treatment resistance — Hypoxic cells are resistant to radiation therapy (which requires oxygen to generate DNA-damaging free radicals) and to many chemotherapy drugs
- Selects for aggressive cells — Hypoxia kills weaker cancer cells — leaving behind a more aggressive, stress-resistant population
- Suppresses immune surveillance — Hypoxia impairs the ability of immune cells to recognise and kill cancer cells
- Activates cancer stem cell pathways — Hypoxia promotes the development of cancer stem cells — a subpopulation of cancer cells with enhanced tumour-initiating and metastatic potential
Hypoxia and Breast Cancer
Hypoxia plays a particularly important role in breast cancer biology — where it has been shown to promote tumour cell proliferation, angiogenesis, invasion and metastasis. Research conducted by Dr. Nishant Kumar Rana during his doctoral studies at Banaras Hindu University demonstrated that CoCl₂-driven chemical hypoxia promotes proliferation in T-47D breast cancer cells in a concentration and cell-type-dependent manner — and identified the roles of hypoxia-regulated miRNAs in activating angiogenic pathways and suppressing apoptosis in these cells.
Hypoxia is also implicated in Postpartum Breast Cancer — where the dramatic tissue remodelling occurring during postpartum involution creates a unique microenvironment that may include regions of hypoxia — promoting tumour cell survival and adaptation during this critical period.
Hypoxia in Other Diseases
Beyond cancer, hypoxia plays important roles in many other diseases:
Sickle Cell Disease
In Sickle Cell Disease — hypoxia triggers the sickling of abnormal haemoglobin molecules — causing red blood cells to adopt a rigid, sickle-like shape that blocks blood vessels and causes vaso-occlusive crises, organ damage and chronic haemolysis. The haemolysis-driven release of free haemoglobin and heme in SCD creates a toxic vascular environment — contributing to Pulmonary Hypertension and other serious complications. This connection between hypoxia, haemolysis and pulmonary hypertension has been studied extensively — including in research conducted by Dr. Nishant Kumar Rana at the University of Colorado Anschutz Medical Campus.
Neurodegeneration
Chronic or intermittent hypoxia contributes to neurodegenerative diseases — including Alzheimer's disease and Parkinson's disease — by promoting oxidative stress, mitochondrial dysfunction and the accumulation of misfolded proteins in neurons.
Cardiovascular Disease
Hypoxia is central to the pathophysiology of heart attacks (myocardial infarction), stroke and Pulmonary Hypertension — conditions in which inadequate oxygen delivery causes irreversible damage to the heart, brain and blood vessels.
High-Altitude Illness
People who ascend rapidly to high altitude without adequate acclimatisation can develop acute mountain sickness (AMS), high-altitude pulmonary oedema (HAPE) or high-altitude cerebral oedema (HACE) — all caused by the acute effects of hypoxia on the body.
Hypoxia in Research and Medicine
Therapeutic Targeting of Hypoxia
The critical role of hypoxia in cancer and other diseases has made it an important therapeutic target:
- Anti-angiogenic therapy — Drugs targeting VEGF (such as bevacizumab) — blocking the formation of tumour blood vessels driven by hypoxic HIF activation
- HIF inhibitors — Drugs targeting HIF-1α or HIF-2α — blocking the master regulator of the hypoxic response
- Hypoxia-activated prodrugs — Drugs specifically designed to be activated under the hypoxic conditions found in tumours — enabling selective killing of hypoxic cancer cells
- Tumour oxygenation strategies — Approaches to improve oxygen delivery to tumours — increasing sensitivity to radiation and chemotherapy
Hypoxia in Laboratory Research
Hypoxia is studied in the laboratory using several approaches:
- Hypoxia chambers — Controlled environments in which cells are cultured under precise low-oxygen conditions
- Chemical hypoxia — Using CoCl₂ or other chemicals to mimic hypoxia in cell culture
- In vivo hypoxia models — Animal models in which hypoxia is induced by exposure to low-oxygen environments or by surgical manipulation of blood vessels